60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research note published on Friday morning,Benzinga reports.

60 Degrees Pharmaceuticals Stock Down 3.1 %

NASDAQ:SXTP opened at $0.87 on Friday. The stock’s 50 day moving average price is $1.09 and its two-hundred day moving average price is $0.72. The firm has a market capitalization of $1.62 million, a price-to-earnings ratio of -0.09 and a beta of 4.78. 60 Degrees Pharmaceuticals has a 12-month low of $0.70 and a 12-month high of $18.36.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.